402 related articles for article (PubMed ID: 11432807)
21. Class II transactivator-mediated regulation of major histocompatibility complex class II antigen expression is important for hematopoietic progenitor cell suppression by chemokines and iron-binding proteins.
Broxmeyer HE; Cooper S; Hangoc G; Chang CH
Exp Hematol; 2006 Aug; 34(8):1078-84. PubMed ID: 16863914
[TBL] [Abstract][Full Text] [Related]
22. Class II transactivator promoter activity is suppressed through regulation by a trophoblast noncoding RNA.
Geirsson A; Paliwal I; Lynch RJ; Bothwell AL; Hammond GL
Transplantation; 2003 Jul; 76(2):387-94. PubMed ID: 12883198
[TBL] [Abstract][Full Text] [Related]
23. Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells.
Sartoris S; Tosi G; De Lerma Barbaro A; Cestari T; Accolla RS
Eur J Immunol; 1996 Oct; 26(10):2456-60. PubMed ID: 8898960
[TBL] [Abstract][Full Text] [Related]
24. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
[TBL] [Abstract][Full Text] [Related]
25. Induction of CIITA and modification of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-gamma: similarities and distinctions with respect to HLA-DR-constitutive B cells.
Rigaud G; De Lerma Barbaro A; Nicolis M; Cestari T; Ramarli D; Riviera AP; Accolla RS
J Immunol; 1996 Jun; 156(11):4254-8. PubMed ID: 8666795
[TBL] [Abstract][Full Text] [Related]
26. IFN regulatory factor-1 plays a central role in the regulation of the expression of class I and II MHC genes in vivo.
Hobart M; Ramassar V; Goes N; Urmson J; Halloran PF
J Immunol; 1997 May; 158(9):4260-9. PubMed ID: 9126988
[TBL] [Abstract][Full Text] [Related]
27. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ
Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433
[TBL] [Abstract][Full Text] [Related]
28. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N
J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831
[TBL] [Abstract][Full Text] [Related]
29. Discoordinate surface expression of IFN-gamma-induced HLA class II proteins in nonprofessional antigen-presenting cells with absence of DM and class II colocalization.
Muczynski KA; Anderson SK; Pious D
J Immunol; 1998 Apr; 160(7):3207-16. PubMed ID: 9531276
[TBL] [Abstract][Full Text] [Related]
30. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter.
Deffrennes V; Vedrenne J; Stolzenberg MC; Piskurich J; Barbieri G; Ting JP; Charron D; Alcaïde-Loridan C
J Immunol; 2001 Jul; 167(1):98-106. PubMed ID: 11418637
[TBL] [Abstract][Full Text] [Related]
31. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines.
Rodríguez T; Méndez R; Del Campo A; Jiménez P; Aptsiauri N; Garrido F; Ruiz-Cabello F
BMC Cancer; 2007 Feb; 7():34. PubMed ID: 17319941
[TBL] [Abstract][Full Text] [Related]
32. Inhibitor (IK) of IFN-gamma induced HLA class II antigens expression also inhibits HLA class II constitutive expression in the human Raji B cell line.
Vedrenne J; Assier E; Pereno R; Bouzinba-Segard H; Azzarone B; Jasmin C; Charron D; Krief P
Oncogene; 1997 Mar; 14(12):1453-61. PubMed ID: 9136989
[TBL] [Abstract][Full Text] [Related]
33. Pathologic expression of MHC class II is driven by mitogen-activated protein kinases.
Martins I; Deshayes F; Baton F; Forget A; Ciechomska I; Sylla K; Aoudjit F; Charron D; Al-Daccak R; Alcaide-Loridan C
Eur J Immunol; 2007 Mar; 37(3):788-97. PubMed ID: 17304627
[TBL] [Abstract][Full Text] [Related]
34. Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain.
Itoh-Lindstrom Y; Piskurich JF; Felix NJ; Wang Y; Brickey WJ; Platt JL; Koller BH; Ting JP
J Immunol; 1999 Sep; 163(5):2425-31. PubMed ID: 10452977
[TBL] [Abstract][Full Text] [Related]
35. CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells.
Meissner M; Whiteside TL; Kaufmann R; Seliger B
Arch Dermatol Res; 2009 Feb; 301(2):189-93. PubMed ID: 19104823
[TBL] [Abstract][Full Text] [Related]
36. Prolonged MHC class II expression and CIITA transcription in human keratinocytes.
Takagi A; Nishiyama C; Kanada S; Niwa Y; Fukuyama K; Ikeda S; Okumura K; Ogawa H
Biochem Biophys Res Commun; 2006 Aug; 347(2):388-93. PubMed ID: 16836979
[TBL] [Abstract][Full Text] [Related]
37. CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant.
Zhou H; Su HS; Zhang X; Douhan J; Glimcher LH
J Immunol; 1997 May; 158(10):4741-9. PubMed ID: 9144488
[TBL] [Abstract][Full Text] [Related]
38. Toxoplasma gondii down-regulates MHC class II gene expression and antigen presentation by murine macrophages via interference with nuclear translocation of STAT1alpha.
Lüder CG; Walter W; Beuerle B; Maeurer MJ; Gross U
Eur J Immunol; 2001 May; 31(5):1475-84. PubMed ID: 11465104
[TBL] [Abstract][Full Text] [Related]
39. Class II transactivator (CIITA) promoter methylation does not correlate with silencing of CIITA transcription in trophoblasts.
Holtz R; Choi JC; Petroff MG; Piskurich JF; Murphy SP
Biol Reprod; 2003 Sep; 69(3):915-24. PubMed ID: 12748124
[TBL] [Abstract][Full Text] [Related]
40. MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma.
Zhao M; Flynt FL; Hong M; Chen H; Gilbert CA; Briley NT; Bolick SC; Wright KL; Piskurich JF
Mol Immunol; 2007 Apr; 44(11):2923-32. PubMed ID: 17300840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
